Study Summary
The purpose of this study is to infusion CD19 CAR-T cells to the patients with relapsed and refractory CD19+ B cell leukemia, to assess the safety and feasibility of this strategy. The CAR enables the T cell to recognize and kill the leukemic cell through the recognition of CD19, a protein expressed of the surface of the leukemic cell in patients with CD19+ leukemia.
Want to learn more about this trial?
Request More InfoInterventions
CyclophosphamideDRUG
patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
FludarabineDRUG
Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
CD19 CAR-TBIOLOGICAL
CD19 CAR-T cells will be administered after completion of the chemotherapy.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The First Affiliated Hospital of Henan University of Science and Technology | Luoyang | Henan | China |
| Henan Cancer Hospital | Zhengzhou | Henan | China |